Neuroscience Focus Areas:
Our other therapy areas

    • {%itemName%}
        {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%itemKeyName%} {%itemBadges%} {%arrowSpan%}
      {%selfProduct%}
    • {%itemName%}
      • {%countries%}
    • {%allMenuItem%}
      • {%languages%}

      • This website is for UK Healthcare Professionals only

      UK-BUO-220048. DOP: April 2022.

      The Patient Experience: Overactive bladder (OAB) can impact on patients' quality of life in many ways

      Definition of OAB: OAB is characterised by urinary urgency, with or without urgency urinary incontinence, usually with increased daytime frequency and nocturia5,6

      patient exp image 1

      URINARY INCONTINENCE (UI):

      • urgency UI:6 involuntary leakage accompanied by urgency
      • stress UI:6 involuntary leakage on effort or exertion, or on sneezing or coughing
      • mixed UI:6 involuntary leakage associated with urgency and also with exertion, effort, sneezing or coughing

      The impacts of OAB on patient quality of life are manifold7-16

      PHYSICAL

      • limitations or cessation of physical activities7
      • disturbed sleep8

      SEXUAL

      • avoidance of sexual contact and intimacy7,9

      DOMESTIC

      • special underwear (pads) and bedding7,9
      • precautions with clothing7,9
      • contributes to need for homecare services and long-term care10

      PSYCHOLOGICAL

      • depression7,11,12
      • loss of self-esteem7
      • embarrassment9

      SOCIAL

      • reduction in social interaction7
      • reliance on toilet accessibility7-9

      OCCUPATIONAL

      • absence from work7
      • decreased productivity7

      Impact of OAB on daily living

      2 out of 3 patients report that their symptoms affect their daily life17

      *CES-D: Center for Epidemiological Studies – Depression. The CES-D is a self-reported depression scale including 20 items, developed to identify depression-related symptoms. Scores range from 0 to 60, with higher scores relating to more depression-related symptoms, and scores of 16 or over indicating depression.13

      OAB: overactive bladder; UI: urinary incontinence.

      BOTOX® is indicated for the management of bladder dysfunctions in adult patients who are not adequately managed with anticholinergics: overactive bladder with symptoms of urinary incontinence, urgency and frequency19

       

      References

      1. Allergan. Data on file. INT/0423/2016
      2. Aurora S K, Winner P et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 2011;51(9):1358-1373
      3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of onabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain 2018;19(1):13
      4. Allergan Ltd. Data on file 014
      5. Abrams P, Cardozo L et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21(2):167-178
      6. Milsom I. Epidemiology of urinary incontinence (UI) and other lower urinary tract symptoms (LUTS), pelvic organ prolapse (POP) and anal (AI) incontinence. Abrams P et al. Incontinence: 6th edition. 2017:50
      7. Tubaro A. Defining overactive bladder: epidemiology and burden of disease. Urology 2004;64(6 Suppl 1):2-6
      8. Coyne K S, Payne C et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health 2004;7(4):455-463
      9. Abrams P, Kelleher C J et al. Overactive bladder significantly affects quality of life. Am J Manag Care 2000;6(11 Suppl):S580-590
      10. Du Moulin M F, Hamers J P et al. Prevalence of urinary incontinence among community-dwelling adults receiving home care. Res Nurs Health 2008;31(6):604-612
      11. Zorn B H, Montgomery H et al. Urinary incontinence and depression. J Urol 1999;162(1):82-84
      12. Irwin D E, Milsom I et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int 2006;97(1):96-100
      13. Stewart W F, Van Rooyen J B et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20(6):327-336
      14. Papanicolaou S, Hunskaar S et al. Assessment of bothersomeness and impact on quality of life of urinary incontinence in women in France, Germany, Spain and the UK. BJU Int 2005;96(6):831-838
      15. Rigby D. Urinary urge incontinence: causes and management strategies. Br J Community Nurs 2005;10(4):172, 174-178
      16. Brown J S, Subak L L et al. Urge incontinence: the patient's perspective. J Womens Health 1998;7(10):1263-1269
      17. Milsom I, Abrams P et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87(9):760-766
      18. Temml C, Haidinger G et al. Urinary incontinence in both sexes: prevalence rates and impact on quality of life and sexual life. Neurourol Urodyn 2000;19(3):259-271
      19. BOTOX® Summary of Product Characteristics. www.medicines.org.uk. Accessed April 2022

      Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use.

      BOTOX® PRESCRIBING INFORMATION

       

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/

      Adverse events should also be reported to AbbVie on [email protected] 

       

      Date of preparation: April 2022. UK-BUO-220016.

       

       

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on [email protected]

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-230225. Date of preparation June 2023. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.